Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The
investigational product Hamsa-1™ comprises of four well-known active components. The therapy
is administrated at a unique dosing regimen that was found to be effective and advantageous
in terms of safety.The product is formulated as an oral suspension, conveniently
administrated by the patients at home and not requiring medical staff assistance. This Phase
IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic
Castration Resistant Prostate Cancer (CRPC) patients.